Eisai Co., Ltd. (4523)

9,268.0
-188.0(-1.99%)
  • Volume:
    1,541,100
  • Bid/Ask:
    9,257.0/9,269.0
  • Day's Range:
    9,178.0 - 9,409.0
  • Type:Equity
  • Market:Japan
  • ISIN:JP3160400002

4523 Overview

Prev. Close
9,456
Day's Range
9,178-9,409
Revenue
645.94B
Open
9,380
52 wk Range
6,705-12,765
EPS
146.91
Volume
1,541,100
Market Cap
2.66T
Dividend (Yield)
160.00
(1.69%)
Average Volume (3m)
2,883,437
P/E Ratio
64.37
Beta
1.01
1-Year Change
6.29%
Shares Outstanding
286,666,418
Next Earnings Date
Aug. 04, 2021
What is your sentiment on Eisai Co., Ltd.?
or
Market is currently closed. Voting is open during market hours.

Eisai Co., Ltd. News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellSellStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong SellStrong Buy
SummaryStrong BuyBuyStrong SellStrong SellStrong Buy

Eisai Co., Ltd. Company Profile

Eisai Co., Ltd. Company Profile

Employees
11237
Market
Japan

Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.